KR20200049356A - Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof - Google Patents
Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof Download PDFInfo
- Publication number
- KR20200049356A KR20200049356A KR1020180132540A KR20180132540A KR20200049356A KR 20200049356 A KR20200049356 A KR 20200049356A KR 1020180132540 A KR1020180132540 A KR 1020180132540A KR 20180132540 A KR20180132540 A KR 20180132540A KR 20200049356 A KR20200049356 A KR 20200049356A
- Authority
- KR
- South Korea
- Prior art keywords
- bellflower
- liquid composition
- ginseng
- stick
- volume
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 12
- 229930182494 ginsenoside Natural products 0.000 title claims description 31
- 238000002360 preparation method Methods 0.000 title description 15
- 244000274050 Platycodon grandiflorum Species 0.000 title description 2
- 235000006753 Platycodon grandiflorum Nutrition 0.000 title description 2
- 241000332371 Abutilon x hybridum Species 0.000 claims abstract description 94
- 239000012141 concentrate Substances 0.000 claims abstract description 39
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 22
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 21
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 claims abstract description 20
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000000346 sugar Nutrition 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 16
- 241000383638 Allium nigrum Species 0.000 claims abstract description 15
- 230000003579 anti-obesity Effects 0.000 claims abstract description 14
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 13
- ZTQSADJAYQOCDD-FDDSVCGKSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O ZTQSADJAYQOCDD-FDDSVCGKSA-N 0.000 claims abstract description 9
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 claims abstract description 9
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 claims abstract description 8
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 claims abstract description 8
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 claims abstract description 8
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 claims abstract description 8
- 150000008163 sugars Chemical class 0.000 claims abstract description 7
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 4
- 235000008434 ginseng Nutrition 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 40
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 40
- 230000032683 aging Effects 0.000 claims description 19
- 241000283707 Capra Species 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 240000001929 Lactobacillus brevis Species 0.000 claims description 9
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims 6
- 238000009835 boiling Methods 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 abstract description 5
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 abstract description 4
- 240000004371 Panax ginseng Species 0.000 description 36
- 239000000243 solution Substances 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 24
- 238000000855 fermentation Methods 0.000 description 19
- 230000004151 fermentation Effects 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 15
- 229940089161 ginsenoside Drugs 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000010025 steaming Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 229930003935 flavonoid Natural products 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 150000002215 flavonoids Chemical class 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- 230000002292 Radical scavenging effect Effects 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 229930182490 saponin Natural products 0.000 description 8
- 150000007949 saponins Chemical class 0.000 description 8
- 235000017709 saponins Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 102000019280 Pancreatic lipases Human genes 0.000 description 5
- 108050006759 Pancreatic lipases Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229940116369 pancreatic lipase Drugs 0.000 description 5
- 240000002234 Allium sativum Species 0.000 description 4
- ZFAHNWWNDFHPOH-YFKPBYRVSA-N S-allylcysteine Chemical compound OC(=O)[C@@H](N)CSCC=C ZFAHNWWNDFHPOH-YFKPBYRVSA-N 0.000 description 4
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 235000004611 garlic Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940040461 lipase Drugs 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- -1 steroidal glycoside compounds Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- JINCXMJGROALLO-UHFFFAOYSA-N Deapio-platycodin D Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1OC9OCC(O)C(O)C9O JINCXMJGROALLO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- XHKCYIRZWRRXNG-UHFFFAOYSA-N Platycodin D3 Natural products OC1C(O)C(OC2C(C(OC3C(C(O)(CO)CO3)O)C(O)CO2)O)C(C)OC1OC1C(O)C(O)COC1OC(=O)C1(C(CC2(C)C3(C)CCC4C5(CO)CO)O)CCC(C)(C)CC1C2=CCC3C4(C)CC(O)C5OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O XHKCYIRZWRRXNG-UHFFFAOYSA-N 0.000 description 2
- ZFAHNWWNDFHPOH-UHFFFAOYSA-N S-Allyl-L-cystein Natural products OC(=O)C(N)CSCC=C ZFAHNWWNDFHPOH-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- HCKUIVZXCXTBEH-PSRBGVDOSA-N deapio-platycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HCKUIVZXCXTBEH-PSRBGVDOSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- XHKCYIRZWRRXNG-COMVGSAYSA-N platycodin D3 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XHKCYIRZWRRXNG-COMVGSAYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WYQZZUUUOXNSCS-YFKPBYRVSA-N (2r)-2-amino-3-(prop-2-enyldisulfanyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CSSCC=C WYQZZUUUOXNSCS-YFKPBYRVSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- WYQZZUUUOXNSCS-UHFFFAOYSA-N S-allylmercapto-L-cysteine Natural products OC(=O)C(N)CSSCC=C WYQZZUUUOXNSCS-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940071182 stannate Drugs 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/24—Non-sugar sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 인체 흡수형 진세노사이드가 강화된 스틱형 용기용 도라지 액상조성물 및 그 제조방법에 관한 것으로, 더 상세하게는 활성산양삼 추출액을 포함하여 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이가 강화되고, 증진된 항산화 활성, 항당뇨 활성 및 항비만 활성을 갖고, 휴대와 섭취가 편리한 스틱 용기용 도라지 액상조성물에 관한 것이다. The present invention relates to a liquid composition of a bellflower for a stick-type container in which a human-absorption-type ginsenoside is strengthened, and more specifically, a human-absorption-type ginsenoside Rd2, F2, Rg3 and a compound including an active wild ginseng extract. K is strengthened, and has enhanced antioxidant activity, anti-diabetic activity and anti-obesity activity, and relates to a bellflower liquid composition for stick containers that are convenient to carry and ingest.
도라지(Platycodon grandiflorum)는 길경, 길경채, 질경 또는 산도라지라고 하며 산과 들에서 자라고 뿌리는 굵고 줄기는 곧으며 높이는 40 ∼ 100 cm 이다. 도라지는 당질을 약 90% 이상 함유하고 있고 단백질이 약 2.5%, 지질 약 0.1%로 보고되어 있다. 도라지는 오랫동안 식용 및 약용으로 사용되어 왔으며, 뿌리에는 2%의 사포닌 및 0.03%의 스테롤(sterol)이 함유되어 있고, 그 외 당류로서는 이눌린(inulin), 플라티코디닌이 함유되어 있다. 도라지의 주요 약리성분인 도라지 사포닌은 platycodin D3, deapioplatycodin D 및 polygalcin D 등이 있으나, 인체 흡수형 진세노사이드는 거의 함유되어 있지 않아서 이를 강화하는 기술의 개발이 요구되고 있다. Platycodon grandiflorum ) is called gilkyung, gilkyungchae, plantain, or mountain bellflower. It grows in the mountains and roots, has thick roots, and is 40-100 cm high. The bellflower contains about 90% or more of sugar and has been reported to have about 2.5% protein and about 0.1% lipid. Bellflower has been used for edible and medicinal purposes for a long time, and the root contains 2% of saponin and 0.03% of sterol, and other sugars include inulin and platinumicodinin. The major pharmacological components of bellflower, such as bellflower saponin, include platycodin D3, deapioplatycodin D, and polygalcin D, but since human-absorptive ginsenosides are rarely contained, it is required to develop a technology to strengthen them.
산양삼은 오가피과에 속하며 다년생 초목인 인삼(Panax ginseng)이 산간의 삼림하의 야생상태에서 자연적으로 성장한 산삼의 씨앗이나 유삼을 인위적으로 산에서 재배한 것을 말하며 이들을 산양삼이라 한다. 또한 예로부터 야생에서 자생한 산삼은 최고의 산삼으로 쳤으며 장뇌삼이라고도 불린다. 인삼의 경우에는 대부분 노두(머리 부분)가 3-7개 정도이나 산양삼은 연령에 따라 그 이상인 것이 많으며 인삼의 뿌리는 굵고 짧으나 산양삼은 길고 가늘다. 산양삼은 여러 효능면에서 재배 인삼보다 효과가 더 높은 것으로 알려져 있으나 이를 뒷받침 할 수 있는 과학적 근거가 인삼에 비해 그리 많지는 않은 것이 현재 실정이다. Goat ginseng belongs to the family Ogapiaceae and refers to wildly grown wild ginseng seeds or ginseng grown wild in the wild under the mountain forest by the perennial vegetation, Panax ginseng . In addition, wild ginseng grown wild in the wild has been considered the best wild ginseng and is also called camphor ginseng. In the case of ginseng, most of the outcrops (heads) are about 3-7, but the amount of wild ginseng is more than that depending on the age. It is known that goats are more effective than cultivated ginseng in many efficacy, but there is not much scientific evidence to support them compared to ginseng.
사포닌은 식물계에 널리 분포하고 있는 트리텔펜과 스테로이드계 배당체 화합물의 총칭이다. 사포닌의 뜻은 라틴어의 sapo(비누)에서 유래되어 이것을 물과 함께 진탕하면 거품을 형성하는 천연계면활성제이다. 삼의 사포닌인 진세노사이드를 함유한 산양삼은 한약처방전에서 천연 자연 산삼 다음으로 효능을 높이 평가하고 있다. 또한 재배인삼과 비교하였을 시 진세노사이드 함량이 높다고 보고되어 있으며 재배된 인삼보다 효능 또한 뛰어남이 알려져 있다. 그러나 알려진 산양삼 관련 가공품들은 진세노사이드 함유량이 기준치 미달이거나 인체 흡수형 진세노사이드는 거의 함유되어 있지 않은 실정이다. 종래 효소나 장내 미생물을 이용하여 인삼에 포함된 진세노사이드를 인체 흡수형으로 전환하는 기술들이 몇몇 개발되어 있으나 (등록특허 10-1751305호), 이들 기술은 비용이 높거나 인체 흡수형 진세노사이드의 증진률이 낮은 문제를 내포하고 있어서, 여전히 인체 흡수형 진세노사이드가 증진된 삼 가공품의 개발이 요구되고 있는 실정이다.Saponin is a generic term for tritelpene and steroidal glycoside compounds widely distributed in plant systems. Saponin is a natural surfactant that originates from the Latin sapo (soap) and forms a bubble when shaken with water. Ginseng ginseng, which contains ginsenoside, the saponin of ginseng, is highly valued after natural natural ginseng in the herbal medicine prescription. In addition, when compared to cultivated ginseng, it is reported that the ginsenoside content is high, and it is known that the efficacy is superior to that of cultivated ginseng. However, known ginseng-related processed products have a ginsenoside content that is less than the reference value or a human-absorbing ginsenoside. Several techniques have been developed for converting ginsenosides contained in ginseng into a human absorption type using conventional enzymes or intestinal microorganisms (Registration No. 10-1751305), but these technologies are expensive or human absorption type ginsenosides Since it has a problem of low enhancement rate, it is still required to develop a processed product having improved human absorption type ginsenosides.
흑마늘은 마늘(Allium sativum for. Pekinense MAKINO)을 발효, 숙성시킨 것으로, 생마늘에 존재하지 않는 S-allylcysteine(SAC)과 S-allyl-mercapto-cysteine이라는 수용성의 황-아미노산이 생성되어 암 예방, 동맥경화 개선, 심장질환의 예방 등의 다양한 약리작용의 효과가 생마늘보다 높은 것으로 알려져 있다. Black garlic is garlic (Allium sativum for. Pekinense MAKINO) is fermented and aged, and water-soluble sulfur-amino acids such as S-allylcysteine (SAC) and S-allyl-mercapto-cysteine that are not present in raw garlic are generated to prevent cancer, improve arteriosclerosis, prevent heart disease, etc. It is known that the effect of various pharmacological effects of is higher than that of raw garlic.
산화적 스트레스(Oxidative stress)는 활성산소 생산계 및 소거계의 균형에 의해 거의 일정하게 유지되고 있던 생체 산화수준이 약제, 방사선, 허혈, 노화 등 여러 가지 요인에 의해 이러한 균형이 무너진 상태를 가리키는 것으로, 과도한 자유 라디칼을 발생시켜 인체의 항산화 기전의 균형을 깨트리고, 산화적 스트레스 결과 세포상해(특히 세포막 지질과 산화), DNA염기 수식에 의한 돌연변이, 세포사(apotosis) 유도 등을 일으켜서 동맥경화증, 퇴행성 뇌질환, 중풍, 파킨슨병, 헌팅턴병, 당뇨, 암, 알쯔하이머, 치매, 노화 등의 다양한 질환의 원인이 되고 있다. 이와 같은 산화적 스트레스는 발생된 라디칼의 소거에 의해 완화될 수 있다. Oxidative stress indicates that the level of bio-oxidation, which has been maintained almost constant by the balance of the free radical production system and scavenging system, indicates that this balance is broken by various factors such as drugs, radiation, ischemia, and aging. Atherosclerosis, degenerative disease by generating excessive free radicals to break the balance of the antioxidant mechanism of the human body, resulting in cellular injury (especially cell membrane lipids and oxidation), DNA base modification, apoptosis induction, etc. Brain diseases, paralysis, Parkinson's disease, Huntington's disease, diabetes, cancer, Alzheimer's, dementia, aging, etc. are causing various diseases. This oxidative stress can be alleviated by the elimination of generated radicals.
알파-글루코시다아제(glucosidase)는 소장점막에 존재하는 효소로서 식품 섭취 시에 탄수화물을 포도당 단위의 단당류로 분해하기 때문에 소화 및 흡수에 필수적이다. 이들 효소의 저해는 탄수화물 분해를 저해하게 하여 결과적으로 포도당 흡수 억제와 혈당상승을 감소시킬 수 있어서, 이들 효소의 저해활성을 갖는 제제는 당뇨 치료제로 사용되고 있다.Alpha-glucosidase is an enzyme present in the mucous membrane of the small intestine and is essential for digestion and absorption because it breaks down carbohydrates into monosaccharides of glucose units when ingesting food. Inhibition of these enzymes can inhibit the degradation of carbohydrates, resulting in inhibition of glucose uptake and reduction of blood glucose, so agents with inhibitory activity of these enzymes are used as therapeutic agents for diabetes.
인체에 흡수된 지방산은 트리글리세라이드(triglyceride)로 재합성되고 과잉으로 존재 시 인체 여러 조직에 축적되는데, 지방 흡수에 리파아제(lipase)가 중요한 역할을 한다. 따라서 리파아제 저해활성을 갖는 제제는 지방이 분해 및 축적되지 않고 체외로 배설되게 함으로서 비만 개선효과를 갖는다. Fatty acids absorbed by the human body are resynthesized into triglyceride and accumulate in various tissues of the human body when present in excess. Lipase plays an important role in fat absorption. Therefore, the lipase inhibitory agent has an effect of improving obesity by allowing fat to be excreted outside the body without decomposition and accumulation.
이에 본 발명자들은 종래 기술의 요구에 부응하기 위해 연구를 지속한 결과, 특정조건의 고온숙성된 숙성 도라지 농축액과 복합발효된 활성산양삼 추출액, 흑마늘 농축액 및 액상당류를 포함하는 도라지 액상조성물은 인체 흡수형 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이가 강화되고 우수한 항산화 활성, 항당뇨 및 항비만 활성을 가지며, 휴대와 먹기가 편리한 스틱형 용기에 적용하기에 적합하다는 것을 확인하고 본 발명을 완성하게 되었다. As a result, the present inventors continued research to meet the demands of the prior art, and as a result, the bellflower liquid composition comprising the matured bellflower concentrate aged with high temperature and the complex fermented active ginseng extract, black garlic concentrate and liquid sugars was absorbed by the human body. Ginsenosides Rd2, F2, Rg3 and compound K have been strengthened, have excellent antioxidant activity, anti-diabetic and anti-obesity activity, and have been confirmed to be suitable for application in a stick-type container that is convenient to carry and eat. .
따라서 본 발명의 목적은 숙성 도라지 농축액과 복합발효된 활성산양삼 추출액, 흑마늘 농축액 및 액상당류를 포함하여, 인체 흡수형 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이가 현저히 강화되고, 증진된 항산화 활성, 항당뇨 및 항비만 활성을 가지며, 휴대와 먹기가 편리한 스틱형 용기용 도라지 액상조성물을 제공하는 것이다. Therefore, the object of the present invention, including the matured bellflower concentrate and the active fermented ginseng extract, black garlic concentrate and liquid sugars, the human absorption type ginsenosides Rd2, F2, Rg3 and compound K are significantly enhanced, enhanced antioxidant activity, It provides anti-diabetic and anti-obesity activities, and provides a bellflower liquid composition for stick-type containers that are convenient to carry and eat.
본 발명의 또 다른 목적은 인체 흡수형 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이가 현저히 강화되고, 증진된 항산화 활성, 항당뇨 및 항비만 활성을 갖고, 휴대와 먹기가 편리한 스틱형 용기용 도라지 액상조성물의 제조방법을 제공하는 것이다. Another object of the present invention is a human-absorptive ginsenoside Rd2, F2, Rg3 and compound K are significantly strengthened, have enhanced antioxidant activity, anti-diabetic and anti-obesity activity, and a bellflower for stick-type containers that are convenient to carry and eat. It is to provide a method for producing a liquid composition.
본 발명의 또 다른 목적은 상기 도라지 액상조성물을 포함하는 항산화 활성, 당뇨 및 비만 개선 및 예방용 기능성 식품을 제공하는 것이다.Another object of the present invention is to provide a functional food for improving and preventing the antioxidant activity, diabetes and obesity, including the bellflower liquid composition.
상기 목적을 달성하기 위하여, 본 발명은 숙성 도라지 농축액 26~30 부피%, 복합발효된 활성산양삼 추출액 3~5 부피%, 흑마늘 농축액 5∼7 부피%, 액상당류 45~55 부피%, 및 나머지 물을 포함하고, 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이가 강화된 스틱형 용기용 도라지 액상조성물을 제공하는 것이다. In order to achieve the above object, the present invention is a mature bellflower concentrate 26-30% by volume, complex fermented active ginseng extract 3-5% by volume, black garlic concentrate 5-7% by volume, liquid sugars 45-55% by volume, and the rest of the water Including, it is to provide a bellflower liquid composition for stick-type containers reinforced with human absorbent ginsenosides Rd2, F2, Rg3, and compound K.
<숙성 도라지 농축액> <Maturation bellflower concentrate>
본 발명에서 숙성 도라지 농축액은 증숙과 고온숙성을 3회 반복한 후 농축하여 제조될 수 있다. The matured bellflower concentrate in the present invention can be prepared by repeating evaporation and high temperature aging three times and then concentrating.
본 발명에서 '증숙(steaming process)'은 100℃에서 30~60분간 수증기로 찌는 것을 의미한다. 증숙시간이 30분 미만인 경우 충분한 증숙이 진행되지 않아 숙성과 같은 후속 단계가 원활하지 않을 수 있고 잡균의 오염이 발생될 수 있으며, 60분 초과하여 증숙될 경우는 오랜 열처리로 도라지의 생리활성성분이 파괴될 수 있다.In the present invention, 'steaming (steaming process)' refers to steaming with water vapor at 100 ℃ for 30-60 minutes. When the steaming time is less than 30 minutes, sufficient steaming does not proceed, so that subsequent steps such as aging may not be smooth and contamination of germs may occur. Can be destroyed.
본 발명에서 '고온숙성'은 70~90℃에서 2~4일간 유지하는 것을 의미한다. 숙성온도가 70℃ 미만이거나 숙성기간이 2일 미만인 경우 숙성이 원활히 이루어지지 않으며, 숙성온도가 90℃ 초과하거나 숙성기간이 4일 초과의 경우 생산된 생리활성물질이 분해되어 함량이 감소될 수 있다.In the present invention, 'high temperature ripening' means maintaining at 70 to 90 ° C for 2 to 4 days. If the aging temperature is less than 70 ℃ or the aging period is less than 2 days, aging does not occur smoothly. When the aging temperature exceeds 90 ℃ or the aging period exceeds 4 days, the produced bioactive substances may decompose and the content may be reduced. .
상기 농축은 증숙과 고온숙성이 3회 반복된 숙성 도라지를 건조 및 분말화하여 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출한 후 여과하여 고형분 함량이 60%이상 되도록 농축하는 것으로 수행된다. The concentration is 10 to 20 times (v / w) hydrolysis by drying and powdering the aged bellflower that has been repeated three times for steaming and high temperature aging, extracted for 5-10 hours at 80-100 ° C, filtered, and the solid content is 60%. It is carried out by concentrating to the ideal.
본 발명의 숙성 도라지 농축액은 생리활성 및 약리활성 성분이 증진된다. The matured bellflower concentrate of the present invention has enhanced physiological and pharmacologically active ingredients.
본 발명에 따른 도라지 액상조성물에서, 숙성 도라지 농축액은 26~30 부피%로 포함되며, 26% 미만 첨가시 생리활성 및 약리활성이 미흡하며, 30% 초과 첨가시 도라지 특유의 맛으로 기호성이 나빠질 수 있다. In the bellflower liquid composition according to the present invention, the matured bellflower concentrate is contained in 26-30% by volume, and when added less than 26%, the physiological and pharmacological activities are insufficient, and when it is added more than 30%, palatability may deteriorate due to the peculiar taste of bellflower. have.
<복합발효된 <Composite fermented 활성산양삼Active goat 추출액> Extract>
본 발명에서 복합발효된 활성산양삼 추출액은 산양삼을 증숙과 고온숙성을 3회 반복한 후 복합발효하고 추출하여 제조할 수 있다. In the present invention, the active fermented ginseng extract that is complex fermented can be prepared by repeating steaming and high temperature aging of the wild ginseng three times, followed by complex fermentation and extraction.
본 발명에서'활성산양삼'은 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이의 함량이 증진되도록 산양삼을 가공된 것을 의미한다. In the present invention, 'active goat ginseng' means that the goat's ginseng is processed so that the content of human absorbed ginsenosides Rd2, F2, Rg3, and compound K is enhanced.
증숙과 고온숙성은 상기 숙성 도라지 농축액에서 정의된 바와 같다. Steaming and hot aging are as defined in the matured bellflower concentrate.
본 발명에서 '복합발효'는 증숙과 고온숙성이 3회 반복된 숙성 산양삼을 락토바실러스 브레비스 BMK484 균주와 락토바실러스 플란타륨 P1201 균주의 복합 종균으로 발효한다.In the present invention, 'composite fermentation' ferments fermented goat ginseng repeated three times of steaming and high temperature fermentation as a complex seed of the Lactobacillus brevis BMK484 strain and the Lactobacillus plantarium P1201 strain.
본 발명에서 복합 종균을 구성하는 하나의 균주인 락토바실러스 브레비스 BMK484 균주는 본 발명자들이 김치로부터 분리/동정하여 국립농업과학원 농업유전자원센터(KACC)에 2016년 12월 12일에 기탁한 균주(수탁번호 KACC92157P)로, 가바(GABA)의 생산성 및 진세노사이드 컴파운드 케이(compound K) 생산성이 탁월하다 (특허출원 10-2017-0152033).One strain constituting the complex seed in the present invention, Lactobacillus brevis BMK484 strain, was isolated / identified from the kimchi by the present inventors and deposited on December 12, 2016 at the National Academy of Agricultural Science, Agricultural Genetic Resource Center (KACC). With the number KACC92157P), the productivity of Gaba and Ginsenoside Compound K are excellent (Patent Application 10-2017-0152033).
본 발명에서 복합종균을 구성하는 또 다른 하나의 균주인 락토바실러스 플란타륨 P1201 균주는 본 발명자들이 발효식품으로부터 분리/동정하여 국립농업과학원 농업유전자원센터(KACC)에 2013년 7월 19일에 기탁한 균주(수탁번호 KACC91848P)로서, 생균제제능이 우수하고 생리활성물질 생산성이 우수한 특성을 갖는다 (등록특허 10-154418호).Another strain constituting the complex spawn in the present invention, Lactobacillus plantarium P1201 strain, was isolated / identified from the fermented foods by the present inventors on July 19, 2013 at the National Institute of Agricultural Science, Agricultural Genetic Resource Center (KACC). As a deposited strain (Accession No. KACC91848P), it has excellent probiotic performance and excellent bioactive material productivity (Registration Patent No. 10-154418).
본 발명의 복합종균을 구성하는 락토바실러스 브레비스 BMK484 균주와 락토바실러스 플란타륨 P1201 균주는 발효 특성이 상호 보완되어 상승작용을 나타낸다. 락토바실러스 브레비스 BMK484 균주는 이형유산발효 (hetero-lactic acid fermentation) 유산균으로 단독 발효 시 유산 생성이 충분하지 않고, 락토바실러스 플란타륨 P1201 균주는 동형유산발효(homo-lactic acid fermentation) 유산균으로 단독 발효 시 유산이 과다하게 생성되는데, 놀랍게도 산양삼을 이들 두 가지 종균을 함께 사용하여 복합발효시 양 균주의 발효 특성이 상호 보완되고 인체 흡수형 진세노사이드함량이 현저히 증진되었다.The Lactobacillus brevis BMK484 strain and Lactobacillus plantarium P1201 strain constituting the complex spawn of the present invention exhibit synergistic effects by complementing the fermentation properties. Lactobacillus brevis BMK484 strain is a hetero-lactic acid fermentation lactic acid bacteria that does not produce enough lactic acid when fermented alone, and the Lactobacillus plantarium P1201 strain is a homo-lactic acid fermentation lactic acid fermentation alone City lactic acid is excessively produced. Surprisingly, the fermentation characteristics of both strains were complemented and the human absorbed ginsenoside content was remarkably improved by using wild ginseng together with these two species.
본 발명에서 복합 종균은 락토바실러스 브레비스 BMK484 균주와 락토바실러스 플란타륨 P1201 균주 각각 별도의 배양액으로서 첨가될 수도 있으며, 혼합 배양된 혼합 배양액으로서 첨가될 수도 있다. 복합종균에서 상기 2종의 균주의 혼합 비율은 3 : 1 ~ 1 : 3(v/v)으로 혼합될 수 있다.In the present invention, the complex seed may be added as a separate culture solution for each of the Lactobacillus brevis BMK484 strain and the Lactobacillus plantarium P1201 strain, or may be added as a mixed culture mixture. The mixing ratio of the two strains in the complex seed can be mixed in a 3: 1 ~ 1: 3 (v / v).
발효는 상기 복합 종균의 배양액을 증숙과 고온숙성이 3회 반복된 숙성 산양삼에 2∼10% (v/w) 농도로 접종하여 25~40℃에서 2 ~ 7일간 발효시키는 것으로 수행될 수 있다. 복합 종균 접종량이 2%(v/w) 미만일 경우에는 발효 속도가 지연될 수 있고 10%(v/w) 초과 시에는 균체 증식 속도가 빨라 활성 진세노사이드의 전환율이 낮으며 신맛이 등이 과다할 수 있으며, 발효 온도가 25℃ 미만일 경우 발효기간이 길어져 잡균의 오염을 초래하고 40℃를 초과할 경우에는 균주의 생육이 정지될 수 있고, 발효 기간이 2일 미만일 경우 발효가 충분하지 않아 생리활성물질 등의 생성이 저조하게 될 수 있으며, 7일을 초과한 경우는 과발효에 의해 생리활성물질이 분해될 수 있다.Fermentation may be performed by inoculating the culture of the complex seed with 2-10% (v / w) concentration of aged wild ginseng, which is repeated three times by steaming and high temperature aging, and fermenting at 25-40 ° C for 2-7 days. The fermentation rate may be delayed when the complex seed inoculation amount is less than 2% (v / w), and when it exceeds 10% (v / w), the cell growth rate is fast, so the conversion rate of active ginsenosides is low and the sour taste is excessive. When the fermentation temperature is less than 25 ° C, the fermentation period becomes longer, causing contamination of germs, and when it exceeds 40 ° C, the growth of the strain may be stopped. The production of active substances and the like may be poor, and when it exceeds 7 days, the bioactive substances may be decomposed by over-fermentation.
또한 발효시, 필요에 따라서, 증숙과 고온숙성이 3회 반복된 숙성 산양삼에 물을 첨가하여 수분이 40~50% (v/w)가 되도록 조정 및/또는 살균한 후, 복합종균을 접종하여 발효할 수 있다. 수분이 함량이 상기 범위일 때 발효 효율이 가장 높다. 40% 이하의 수분함량일 경우 미생물이 생존 혹은 생육을 위한 수분이 충분하지 않아 원활한 발효가 진행되지 않고 50% 이상의 경우 발효 종료 후 건조 시간과 비용이 많이 들 수 있으며, 살균 처리를 하지 않을 경우 잡균의 오염 등으로 원활한 발효가 진행되지 않을 수 있다.In addition, upon fermentation, if necessary, water is added to aged wild ginseng that has been repeated three times for steaming and high-temperature aging to adjust and / or sterilize the water to be 40-50% (v / w), and then inoculate the complex seed. Can ferment. The fermentation efficiency is highest when the moisture content is in the above range. If the water content is less than 40%, the microorganism does not have sufficient moisture for survival or growth, and smooth fermentation does not proceed. In the case of 50% or more, drying time and cost may be high after completion of fermentation. Smooth fermentation may not proceed due to contamination.
추출은 복합발효된 산양삼을 건조 및 분말화하여 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출한 후 여과하여 수행된다(고형분 1% 이상).Extraction is carried out by drying and pulverizing the complex fermented wild ginseng by 10-20 times (v / w) hydrolysis, extracting it at 80-100 ° C for 5-10 hours, and filtering it (solid content 1% or more).
본 발명의 복합발효된 활성산양삼 추출액은 도라지 액상조성물에 첨가시에 인체 흡수형 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이가 강화되게 한다. The complex fermented active ginseng extract of the present invention allows the human absorbed ginsenosides Rd2, F2, Rg3 and compound K to be strengthened when added to the bellflower liquid composition.
<< 흑마늘Black garlic 농축액> Concentrate>
흑마늘 농축액은 고온숙성으로 제조된 흑마늘에 10∼20배(v/w) 가수하여 80∼100℃에서 5∼10시간 동안 추출한 후 여과하여 고형분 함량이 6% 이상 되도록 농축하여 제조하거나, 상업적으로 용이하게 입수할 수도 있다. The black garlic concentrate is prepared by high-aged aging
<스틱형 용기용 도라지 액상조성물 제조> <Preparation of bellflower liquid composition for stick type container>
숙성 도라지 농축액 26~30 부피%, 복합발효된 활성산양삼 추출액 3~5 부피%, 흑마늘 농축액 5∼7 부피%, 액상당류 45~55 부피%와 나머지 물을 혼합하여, 스틱형 용기에 충진한다.The matured bellflower concentrate is 26-30% by volume, the complex fermented active ginseng extract is 3-5% by volume, the black garlic concentrate is 5-7% by volume, the liquid sugar is 45-55% by volume, and the remaining water is filled in a stick-type container.
본 발명에서 ‘액상당류’는 액상과당, 벌꿀, 프락토올리고당, 유기설탕 등을 단독 또는 조합하여 포함할 수 있다. In the present invention, 'liquid sugar' may include liquid fructose, honey, fructooligosaccharide, organic sugar, or the like alone or in combination.
본 발명에서 액상당류는 45~55 부피%로 첨가하여 혼합한다. 액상당류을 45 부피% 미만으로 포함되는 경우는 묽은 액상으로 섭취가 불편하며, 55 중량% 초과로 포함되는 경우 단맛이 강할 수가 있다.In the present invention, liquid sugars are added and mixed at 45 to 55% by volume. When the liquid saccharide is contained in less than 45% by volume, it is inconvenient to consume in a dilute liquid, and when it is contained in excess of 55% by weight, the sweetness may be strong.
필요에 따라서, 본 발명의 도라지 액상조성물은 유청분말, 벌집추출물, 과일 농축액, 한약재 농축액, 및/또는 감미료(아스파탐, 스테비아 등) 등을 추가로 포함할 수 있다. If necessary, the bellflower liquid composition of the present invention may further include whey powder, honeycomb extract, fruit concentrate, herbal medicine concentrate, and / or sweetener (aspartame, stevia, etc.).
본 발명에 따른 도라지 액상조성물은 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이의 함량이 각각 0.14 mg/mL, 0.05 mg/mL, 0.11 mg/mL 및 0.05 mg/mL로 강화된다(표 2, 도 2).The bellflower liquid composition according to the present invention is enriched in ginsenosides Rd2, F2, Rg3 and compound K with 0.14 mg / mL, 0.05 mg / mL, 0.11 mg / mL and 0.05 mg / mL, respectively (Table 2, FIG. 2).
또한 본 발명에 따른 도라지 액상조성물은 페놀릭스 및 플라보노이드스의 함량이 증진되어 우수한 항산화 활성을 갖고 우수한 알파-글루코시다아제 저해활성과 췌장 리파아제 저해활성도 가져셔 항당뇨 활성 및 항비만 활성도 현저히 증진되고 (도 3, 도 4, 표 3), 스틱형 용기에 충전하고 섭취가 용이한 정도의 점도를 가진다. In addition, the bellflower liquid composition according to the present invention has an excellent antioxidant activity by increasing the content of phenolics and flavonoids, and also has excellent alpha-glucosidase inhibitory activity and pancreatic lipase inhibitory activity, thereby significantly improving anti-diabetic activity and anti-obesity activity ( 3, 4, Table 3), it is filled in a stick-type container and has a viscosity of easy intake.
본 발명의 또 다른 목적에 따라서, 본 발명은 According to another object of the present invention, the present invention
ⅰ) 도라지를 100℃에서 30~60분간 증숙과 증숙된 도라지를 70∼90℃에서 2~4일 고온숙성을 3회 반복한 후 농축하여 숙성 도라지 농축액을 제조하는 단계; Iv) preparing the matured bellflower concentrate by repeating evaporation of the bellflower at 100 ° C for 30 to 60 minutes and high temperature aging for 2 to 4 days at 70 to 90 ° C for 3-4 days;
ⅱ) 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복한 후 락토바실러스 브레비스 BMK484 균주와 락토바실러스 플란타륨 P1201 균주의 복합 종균으로 발효하여 추출하여 복합발효된 산양삼 추출액을 제조하는 단계; 및 Ii) After culturing wild ginseng at 100 ℃ for 30-60 minutes and repeating high-temperature aging for 2-4 days at 70-90 ℃ for steamed wild ginseng 3 times, complex strains of Lactobacillus brevis BMK484 strain and Lactobacillus plantarium P1201 strain By fermenting and extracting to prepare a complex fermented wild ginseng extract; And
ⅲ) 숙성 도라지 농축액 26~30 부피%, 복합발효된 활성산양삼 추출액 3~5 부피%, 흑마늘 농축액 5∼7 부피%, 액상당류 45~55 부피% 및 나머지 물을 혼합하여 스틱형 용기에 충진하는 단계를 포함하여 이루어지는 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이가 강화되고, 증진된 항산화 활성 및 항당뇨 및 항비만 활성을 갖는 스틱형 용기용 도라지 액상조성물의 제조방법을 제공한다. Iv) 26 ~ 30% by volume of aged bellflower concentrate, 3 ~ 5% by volume of complex fermented active ginseng extract, 5 ~ 7% by volume of black garlic concentrate, 45 ~ 55% by volume of liquid sugar, and the remaining water to fill the stick-type container Provided is a method for preparing a bellflower liquid composition for a stick-type container having enhanced human body absorption type ginsenoside Rd2, F2, Rg3 and compound K comprising steps, and having enhanced antioxidant activity and anti-diabetic and anti-obesity activity.
단계 ⅰ): 숙성 도라지 농축액 제조Step iv): Preparation of aged bellflower concentrate
숙성 도라지 농축액 제조공정은 상기에 기재된 바와 같다. The manufacturing process of the matured bellflower concentrate is as described above.
도라지는 2년근 이상의 도라지를 사용하고, 증숙은 통상의 찜기와 같은 증숙기를 사용하여 수행할 수 있다. The bellflower uses bellflower of 2 years or more, and steaming can be carried out using a steaming device such as a conventional steamer.
증숙된 도라지의 고온숙성시 개방용기를 사용하여 수분이 증발되게 하거나, 밀폐용기를 사용하여 수분이 증발되지 않게 하여 수행할 수 있다.When the steamed bellflower is aged at a high temperature, moisture may be evaporated using an open container, or moisture may not be evaporated using a closed container.
여과는 2 ~ 8 mm 여과필터로 여과하며, 농축은 열을 가하는 열 농축 방법 혹은 감압 농축 방법으로 고형분 함량이 60% 이상 되게 한다. Filtration is filtered with a 2 to 8 mm filtration filter, and the concentration is 60% or more of the solid content by a heat-concentrating method or a reduced-pressure concentrating method.
단계 ⅱ): 복합발효된 Step ii): Co-fermented 산양삼Goat 추출액 제조 Preparation of extract
복합발효된 산양삼 추출액을 제조공정은 상기에 기재된 바와 같다. The manufacturing process of the complex fermented wild ginseng extract is as described above.
산양삼은 3년근 이상의 산양삼을 사용한다.Goat ginseng is used for more than 3 years.
ⅲ) 도라지 액상조성물 제조Ⅲ) Preparation of bellflower liquid composition
숙성 도라지 농축액 26~30 부피%, 복합발효된 활성산양삼 추출액 3~5 부피%, 흑마늘 농축액 5∼7 부피%, 액상당류 45~55 부피% 및 나머지 물을 혼합하여 스틱형 용기에 충진한다. The matured bellflower concentrate 26 ~ 30% by volume, the complex fermented active ginseng extract 3 ~ 5% by volume, the black garlic concentrate 5 ~ 7% by volume, the liquid sugar 45 ~ 55% by volume, and the remaining water are mixed and filled into a stick-type container.
혼합은 상기의 재료들을 교반 혼합기를 사용하여 당업계에서 알려진 통상의 방법으로 수행될 수 있다. 충진은 스텐드 스틱충진기를 사용하는 방법으로 당업계에서 알려진 통상의 방법으로 수행될 수 있다.Mixing can be carried out by the conventional methods known in the art using a stirring mixer for the above materials. The filling may be performed by a conventional method known in the art by using a stand stick filling machine.
필요에 따라서, 본 발명의 제조방법은 단계 ⅲ)에서, 유청분말, 벌집추출물, 과일 농축액, 한약재 농축액, 및/또는 감미료(아스파탐, 스테비아 등)를 추가로 혼합할 수 있다. If necessary, the manufacturing method of the present invention, in step iii), whey powder, honeycomb extract, fruit concentrate, herbal medicine concentrate, and / or sweeteners (aspartame, stevia, etc.) may be further mixed.
본 발명의 제조방법에 의해 제조된 도라지 액상조성물은 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이의 함량이 강화되고, 페놀릭스 및 플라보노이드스의 함량이 강화되어 증진된 항산화 활성, 항당뇨 활성 및 항비만 활성을 갖는다. The bellflower liquid composition prepared by the production method of the present invention has enhanced content of ginsenosides Rd2, F2, Rg3 and compound K, enhanced content of phenolics and flavonoids, and enhanced antioxidant activity, anti-diabetic activity and anti- Obesity activity.
발명의 또 다른 목적에 따라서, 본 발명은 상기 제조방법에 의해 제조된 액상 조성물을 포함하는 항산화 활성, 당뇨 및 비만 개선 및 예방 기능성을 갖는 식품을 제공한다.According to another object of the present invention, the present invention provides a food having antioxidative activity, diabetes and obesity improvement and prevention functions, including a liquid composition prepared by the above manufacturing method.
본 발명에서 식품은 본 발명의 도라지 액상조성물을 그대로 이용하거나, 음료, 젤리, 캡슐 등의 형태의 제품의 형태로 가공될 수 있다.In the present invention, the food product may use the bellflower liquid composition of the present invention as it is, or may be processed in the form of a product such as a beverage, jelly, or capsule.
본 발명에 따른 복합발효된 활성산양삼 추출액을 포함하는 스틱형 용기용 도라지 액상조성물은 진세노사이드 Rd2, F2, Rg3와 컴파운드 케이의 함량이 강화되어 있고, 더불어 페놀릭스 및 플라보노이드스의 함량이 증진되어 우수한 항산화 활성, 알파-글루코시다제 저해활성과 췌장 리파아제 저해활성도 가져서, 항당뇨 활성 및 항비만 활성이 증진되어 기능성 식품의 소재로 사용될 수 있다. 또한 스틱형 용기용으로 휴대와 섭취가 용이하다. The bellflower liquid composition for a stick-type container containing the complex fermented active ginseng extract according to the present invention has an enhanced content of ginsenosides Rd2, F2, Rg3 and compound K, and the content of phenolics and flavonoids is enhanced. It has excellent antioxidant activity, alpha-glucosidase inhibitory activity, and pancreatic lipase inhibitory activity, and thus, anti-diabetic activity and anti-obesity activity can be enhanced and used as a material for functional food. Also, it is easy to carry and consume for stick-type containers.
본 발명에 따른 기능성 식품은 우수한 항산화 활성, 항당뇨 활성 및 항비만 활성을 가져서, 비만 및 당뇨병 개선용으로 사용될 수 있다.Functional food according to the present invention has excellent antioxidant activity, anti-diabetic activity and anti-obesity activity, it can be used for obesity and diabetes improvement.
도 1은 본 발명에 따른 스틱형 용기용 도라지 액상조성물의 제조공정의 일례를 나타낸다.
도 2는 본 발명에 따른 스틱형 용기용 도라지 액상조성물의 진세노사이드 HPLC 크로마토그램을 나타낸 것이다. 도 2a는 비교예의 진세노사이드 HPLC 크로마토그램이며, 도 2b는 실시예의 진세노사이드 HPLC 크로마토그램이다. 도 2c는 도라지 사포닌 표준품의 HPLC 크로마토그램을 나타낸 것이다.
도 3는 본 발명에 따른 스틱형 용기용 도라지 액상조성물의 항산화 활성을 나타낸 것이다. 도 3a는 DPPH 라디칼 소거활성을 나타내고, 도 3b는 ABTS 라디칼 소거활성을 나타내고, 도 3c는 FRAP 환원력을 나타낸다.
도 4는 본 발명에 따른 스틱형 용기용 도라지 액상조성물의 소화효소 저해활성을 나타낸 것이다. 도 4a는 알파-글루코시다아제 저해활성을 나타내고, 도 3b는 췌장-리파아제 저해활성을 나타낸다. 1 shows an example of a manufacturing process of a bellflower liquid composition for a stick-type container according to the present invention.
Figure 2 shows the ginsenoside HPLC chromatogram of the bellflower liquid composition for a stick-type container according to the present invention. Figure 2a is a ginsenoside HPLC chromatogram of the comparative example, Figure 2b is a ginsenoside HPLC chromatogram of the example. Figure 2c shows the HPLC chromatogram of the bellflower saponin standard.
Figure 3 shows the antioxidant activity of the bellflower liquid composition for a stick-type container according to the present invention. FIG. 3A shows DPPH radical scavenging activity, FIG. 3B shows ABTS radical scavenging activity, and FIG. 3C shows FRAP reducing power.
Figure 4 shows the digestive enzyme inhibitory activity of the bellflower liquid composition for a stick-type container according to the present invention. 4A shows alpha-glucosidase inhibitory activity, and FIG. 3B shows pancreatic-lipase inhibitory activity.
다음의 실시예를 통해 본 발명이 보다 더 구체적으로 설명된다. 이들 실시예들은 본 발명을 예시하기 위한 것이며 본 발명의 범위가 이들에 의해 제한되어서는 아니 된다.The present invention is described in more detail through the following examples. These examples are intended to illustrate the invention and the scope of the invention should not be limited by them.
제조예 1: 숙성 도라지 농축액 제조Preparation Example 1: Preparation of aged bellflower concentrate
도라지는 경상남도 함양군 백전면 일대에서 2년 이상 재배된 것을 구입하여 사용하였다. 도라지 10 kg을 흐르는 물에 3회 세척하고 완전히 물기를 제거한 후, 5 kg을 찜기통에 담은 후 100℃에서 60분간 증숙하였다. 증숙된 도라지를 건조 채반에 담아 수분이 증발되게 하면서 75℃에서 3일간 숙성시킨다. 3일간 숙성되어 건조된 도라지에 다시 수분(수분 함량 약 40%)을 첨가하고 100℃에서 60분간 증숙하고 75℃에서 3일간 재숙성시킨다. 2회 숙성되어 건조된 도라지에 다시 수분을 첨가하고 100℃에서 60분간 증숙하고 75℃에서 3일간 마지막 숙성시킨 후, 50℃에서 2일 건조시킨 후 분쇄기로 100메쉬 이하로 분쇄하여 분말을 제조하였다. 분말 50 g에 10배인 정제수 500 mL을 가하고 100℃에서 8시간 추출하고 8 mm 여과필터로 여과한 후 여과액을 고형분 함량이 60%이상 되도록 농축하여 숙성 도라지 농축액을 제조하였다 (도 1). The bellflower was purchased and used for more than 2 years in Baekjeon-myeon, Hamyang-gun, Gyeongsangnam-do. After washing the
제조예 2: 복합발효된 활성산양삼 추출액 제조Preparation Example 2: Preparation of complex fermented active ginseng extract
산양삼은 함양군 서상면 일대에서 3년 이상 재배된 산양삼을 구입하여 사용하였다. 산양삼 10 kg을 흐르는 물에 3회 세척하고 완전히 물기를 제거한 후, 5 kg을 찜기통에 담은 후 100℃에서 60분 증숙하였다. 증숙된 산양삼을 건조 채반에 담아 수분이 증발되게 하면서 75℃에서 3일간 숙성시킨다. 3일간 숙성되어 건조된 산양삼에 다시 수분(수분 함량 약 40%)을 첨가하고 100℃에서 60분 증숙하고 75℃에서 3일간 재숙성시킨다. 2회 숙성되어 건조된 산양삼에 다시 수분을 첨가하고 100℃에서 60분 증숙하고 75℃에서 3일간 마지막 숙성시켜 숙성 산양삼을 제조하였다. Goat ginseng was purchased and used for more than three years in the area of Seosang-myeon, Hamyang-gun. After washing 3 times with 10 kg of wild ginseng in running water and completely removing the water, 5 kg was put in a steamer and steamed at 100 ° C for 60 minutes. The boiled wild ginseng is placed on a dry plate and aged at 75 ℃ for 3 days while allowing the water to evaporate. After maturing for 3 days, water (moisture content of about 40%) is added again to the dried ginseng, dried for 60 minutes at 100 ° C, and re-aged for 3 days at 75 ° C. Ripened wild ginseng was prepared by adding moisture to the dried and dried goat ginseng twice, steaming at 100 ° C for 60 minutes, and finally aged at 75 ° C for 3 days.
증숙된 산양삼을 500 g을 발효용기에 나누어 넣고 동량의 정세수(0.5 L)를 첨가하고 1시간동안 수화시켜 수분 함량을 약 50% 정도로 되게 조정한 후 120℃에서 30분간 살균하고, 락토바실러스 플란타륨 P1201 균주 및 락토바실러스 브레비스 BMK484 균주를 각각 맥아엑기스 액체배지에서 종균으로 배양하며 1:1 비율로 혼합한 복합종균을 5% (v/w)로 접종하고 30℃에서 7일간 발효시켰다. 그리고 나서 50℃에서 2일 건조시킨 후 분쇄기로 100메쉬 이하로 분쇄하여 분말을 제조한 후, 분말 50 g에 10배인 정제수 500 mL을 가하고 100℃에서 8시간 추출하고 8 mm 여과필터로 여과하여 복합발효된 활성산양삼 추출액(고형분 1% 이상)을 제조하였다 (도 1). After dividing 500 g of boiled wild ginseng into a fermentation container, add the same amount of purified water (0.5 L), hydrate for 1 hour, adjust the water content to about 50%, sterilize at 120 ° C for 30 minutes, and Lactobacillus planta Lium P1201 strain and Lactobacillus brevis BMK484 strain were each cultured as strains in malt extract liquid medium and inoculated with 5% (v / w) of mixed strains in a 1: 1 ratio and fermented at 30 ° C for 7 days. Then, dried at 50 ° C for 2 days, pulverized to 100 mesh or less using a grinder to prepare a powder, 500 mL of 10 times purified water was added to 50 g of powder, extracted for 8 hours at 100 ° C, and filtered through an 8 mm filtration filter. Fermented active ginseng extract (solid 1% or more) was prepared (FIG. 1).
제조예 3: 스틱형 용기용 도라지 액상조성물 제조Preparation Example 3: Preparation of bellflower liquid composition for stick type container
상기 제조예 1 및 2에서 제조된 숙성 도라지 농축액과 복합발효된 활성산양삼 추출액을 이용하여 하기 표 1과 같은 배합비율로 혼합하여 도라지 액상조성물을 제조하였다.Using the aged bellflower concentrate prepared in Preparation Examples 1 and 2 and the complex fermented active ginseng extract, the mixture was mixed at the mixing ratio as shown in Table 1 to prepare a bellflower liquid composition.
흑마늘 농축액은 고형분 6%인 것으로 구입하여 사용하였고(㈜EFG) 그 외 액상과당 등의 재료들도 시중에 판매되는 것을 구입하였다.The black garlic concentrate was purchased with a solid content of 6% (EFG Co., Ltd.) and other materials such as liquid fructose were also purchased on the market.
상기의 재료들을 교반 혼합기를 사용하여 혼합하였고 스텐드 스틱충진기를 사용하여 스틱포장지에 12 mL씩 충진하였다 (도 1).The above materials were mixed using a stirring mixer, and 12 mL of the stick packaging was filled using a stand stick filling machine (FIG. 1).
시험예Test example
제조예 3에서 제조된 실시예의 도라지 액상조성물의 인체 흡수형 진세노사이드 함량, 페놀릭스와 플라보노이드스 함량, 항산화 활성, 항당뇨 활성과 항비만 활성, 영양성분, 이화학적 특성, 유리아미노산을 분석하였다.The body-absorbing ginsenoside content, phenolics and flavonoids content, antioxidant activity, anti-diabetic activity and anti-obesity activity, nutrients, physicochemical properties, and free amino acids of the bellflower liquid composition of the example prepared in Preparation Example 3 were analyzed. .
시험예Test example 1. 인체 흡수형 진세노사이드 함량 분석 1. Human absorption type ginsenoside content analysis
제조예 3에서 제조된 도라지 액상조성물(실시예)과 시중에 판매되고 있는 도라지 액상조성물(H사 판매제품, 비교예)에 대한 인체 흡수형 진세노사이드 함량을 기능성식품 분석법에 기술된 방법을 변형하여 고압액체크로마토그래피(HPLC, high press liquid chromatograph)를 사용하여 비교 분석하였다.Modified the method described in the functional food analysis method for the human absorbed ginsenoside content for the bellflower liquid composition prepared in Preparation Example 3 (example) and the commercially available bellflower liquid composition (product sold by H company, comparative example). Then, it was compared and analyzed using high pressure liquid chromatography (HPLC).
구체적으로는 각각의 도라지 액상조성물에 HPLC용 물을 2배(v/v)로 첨가하고 혼합한 후 0.45㎛ 멤브레인 필터로 여과한 후 분석시료로 사용하였다. 분석 컬럼은 TSKgel ODS-100Z을 사용하여 시료주입량 10 ㎕, 온도는 30℃ 측정파장은 203 nm, 유속은 1.0 mL/min으로 하였고 이동상으로는 A용액은 HPLC water, B용액은 아세토니트릴을 사용하였다. HPLC 분석 조건은 이동상 용액은 0분때 A용액 81% : B용액 19%로 흘려주고 15분때에는 A용액 80% : B용액 20%로 흘려주고 40분때 A용액 77% : B용액 23%, 42분때 A용액 70% : B용액 30%, 75분때에 A용액 65% : B용액 35%, 80분때에 A용액 30% : B용액 70%, 90분때에 A용액 10% : B용액 90%로 이동상을 흘려주었다. 분석된 실시예(본 발명의 도라지 액상조성물)과 비교예(시중 판매중인 도라지 액상조성물, H사 판매제품)의 인체 흡수형 진세노사이드 함량을 표 2 및 도 2에 나타내었다.Specifically, HPLC water was added to each bellflower liquid composition twice (v / v) and mixed, followed by filtration through a 0.45 μm membrane filter and used as an analysis sample. As an analytical column, TSKgel ODS-100Z was used to make a sample injection volume of 10 µl, a temperature of 30 ° C, a measurement wavelength of 203 nm, and a flow rate of 1.0 mL / min. As the mobile phase, A solution was used with HPLC water and B solution with acetonitrile. As for HPLC analysis conditions, the mobile phase solution flows to A solution 81%: B solution 19% at 0 minutes, A
상기 표 1에 나타낸 바와 같이, 비교예에는 인체 흡수형 진세노사이드가 검출되지 않았으며, 실시예에는 진세노사이드 Rd2가 0.14 mg/㎖, F2가 0.05 mg/㎖, Rg3가 0.11 mg/㎖ 및 컴파운드 케이가 0.05 mg/㎖로 측정되었다. As shown in Table 1, in the comparative example, no human absorbable ginsenoside was detected, and in the example, ginsenoside Rd2 was 0.14 mg / ml, F2 was 0.05 mg / ml, Rg3 was 0.11 mg / ml, and Compound K was measured to be 0.05 mg / ml.
도 2에 나타난 바와 같이, 비교예의 도라지 액상조성물은 도라지 사포닌인 platycodin D3, deapioplatycodin D와 polygalcin D만 검출되었으나, 실시예의 도라지 액상조성물은 상기 도라지 사포닌 3종 이외에 인체 흡수형 진세노사이드인 Rd2, F2, Rg3, 컴파운드케이(C.K)가 현저히 강화됨을 알 수 있다 (도 2, 표 2).As shown in Fig. 2, the bellflower liquid composition of the comparative example was detected only platycodin D3, deapioplatycodin D, and polygalcin D, which are bellflower saponins, but the bellflower liquid composition of the examples was human-absorbed ginsenosides Rd2, F2 in addition to the bellflower saponins 3 , Rg3, it can be seen that the compound K (CK) is significantly enhanced (Fig. 2, Table 2).
시험예Test example 2. 총 2. Total 페놀릭스Phenolic 및 총 And gun 플라보노이드스Flavonoids 함량 분석 Content analysis
제조예 3에서 제조된 도라지 액상조성물(실시예)과 시중에 판매되고 있는 도라지 액상조성물(H사 판매제품, 비교예)에 대해 총 페놀릭스 및 플라보노이드스 함량을 Folin-Denis 및 Davis법으로 비교 분석하였다.Comparative analysis of total phenolics and flavonoids content by Folin-Denis and Davis method for the bellflower liquid composition (Example) prepared in Preparation Example 3 and the commercially available bellflower liquid composition (Product sold by H company, comparative example) Did.
총 페놀릭스 함량은 각각의 액상조성물을 물로 100배 희석하고 이 희석용액 0.5 mL와 2N Folin-Ciocalteu 페놀 반응시약 0.5 mL를 시험관에 분주하고 25% Na2CO3 용액 0.5 mL를 추가 첨가한 후 30℃에서 1시간 발색반응을 진행하였다. 1시간 후 발색된 청색을 분광광도계를 사용하여 750 nm에서 흡광도를 측정하고 갈산을 이용한 표준검량곡선으로부터 그 함량을 산출하여 표 3에 나타내었다. The total phenolics content is diluted 100 times with each liquid composition, and 0.5 mL of this dilution solution and 0.5 mL of 2N Folin-Ciocalteu phenol reaction reagent are dispensed into a test tube, and 0.5 mL of 25% Na 2 CO 3 solution is added and 30 mL is added. Coloring reaction was carried out for 1 hour at ℃. After 1 hour, the absorbed blue color was measured at 750 nm using a spectrophotometer, and its content was calculated from a standard calibration curve using gallic acid and shown in Table 3.
총 플라보노이드스 함량은 총 페놀릭스 함량과 각각의 액상조성물을 물로 100배 희석하고 이 희석용액 1 mL에 디에틸렌글리콜 1 mL를 첨가 및 혼합하고 여기에 1N NaOH 용액 0.01 mL 추가하여 37℃의 수욕상에서 1시간 반응을 진행하였다. 1시간 후 420 nm에서 흡광도를 측정하고 루틴을 이용한 표준검량곡선으로부터 그 함량을 산출하여 표 3에 나타냈다.The total flavonoids content is 100 times the total phenolics content and each liquid composition diluted with water, 1 mL of diethylene glycol is added to and mixed with 1 mL of this dilution solution, and 0.01 mL of 1N NaOH solution is added thereto in a water bath at 37 ° C. The reaction proceeded for 1 hour. After 1 hour, absorbance was measured at 420 nm, and the content was calculated from a standard calibration curve using a routine, and the results are shown in Table 3.
표 3에 나타낸 바와 같이, 비교예에 비하여 본 발명의 도라지 액상조성물(실시예)의 총 페놀릭스와 총 플라보노이드스 함량은 각각 2.56mg/㎖ 및 0.67mg/㎖로 높게 나타났다. 특히 총 플라보노이드스는 비교예에 비하여 약3배 증진되었다.As shown in Table 3, the total phenolics and total flavonoids contents of the bellflower liquid composition of the present invention (Example) were higher than those of the comparative examples, respectively, at 2.56 mg / ml and 0.67 mg / ml. In particular, total flavonoids were improved about 3 times compared to the comparative example.
시험예Test example 3. 항산화 활성 분석 3. Antioxidant activity analysis
실시예의 도라지 액상조성물과 비교예의 도라지 액상조성물에 대하여 항산화 효과의 지표인 DPPH, ABTS 및 FRAP 환원력을 측정하여 분석하였다.For the bellflower liquid composition of the example and the bellflower liquid composition of the comparative example, DPPH, ABTS and FRAP reducing powers, which are indicators of antioxidant effects, were measured and analyzed.
<DPPH 라디칼 소거활성><DPPH radical scavenging activity>
구체적으로는 실시예의 도라지 액상조성물과 비교예의 도라지 액상조성물을 증류수로 1,000배, 500배, 200배 희석한 분석시료를 각각 0.2 mL와 DPPH 용액 0.(1.5×10-4M) 0.8 mL를 혼합하고 30분간 암실에서 반응시키고 517 nm에서 흡광도를 측정하였다. DPPH 라디칼 소거활성의 음성 대조구는 시료 대신 증류수를 사용하여 동일한 방법으로 수행하여 흡광도의 차이를 다음과 같은 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 3a에 나타내었다:Specifically, 0.2 mL and 0.8 mL of
라디칼 소거활성(%)=[1-(음성대조구 흡광도/실험구 흡광도)]×100Radical scavenging activity (%) = [1- (negative control absorbance / experiment absorbance)] × 100
도 3a에 도시된 바와 같이, 200배 희석한 경우 각각 47.09%(비교예)와 60.23%(실시예)의 DPPH 라디칼 소거활성을 나타낸바, 실시예가 약 30% 증진된 것을 알 수 있다.As shown in FIG. 3A, when diluting 200-fold, the DPPH radical scavenging activity of 47.09% (comparative example) and 60.23% (example), respectively, was found to be improved by about 30%.
<ABTS 라디칼 소거활성><ABTS radical scavenging activity>
ABTS 라디칼 소거활성은 2-azino-bis의 청색을 띤 라디칼의 감소 정도에 따라 항산화 활성을 측정하는 방법이다. 이 방법은 물질의 항산화 활성에 의해 ABTS 양이온이 소거되어 청록색 또는 무색으로 탈색되는 원리로서 탈색 반응이 1분 내에 종료되므로 짧은 시간에 측정이 가능한 장점을 가진다.ABTS radical scavenging activity is a method of measuring antioxidant activity according to the degree of reduction of a blue-colored radical of 2-azino-bis. This method is a principle in which the ABTS cation is eliminated by the antioxidant activity of the substance to decolorize in blue-green or colorless, and the decolorization reaction is completed within 1 minute, so it has the advantage of being able to measure in a short time.
ABTS 라디칼 소거활성 측정은 우선 K2S2O8 시약과 메탄올을 2:1로 섞어 암실에서 16시간 반응시켜 양이온 라디칼을 우선 생성시키고 이를 다시 메탄올로 섞어 732 nm에서 흡광도 수치가 0.8±0.2가 되도록 조절한 ABTS 시약을 사용하였다. To measure the ABTS radical scavenging activity, first mix the K 2 S 2 O 8 reagent and methanol in a 2: 1 reaction for 16 hours in the dark to generate a cationic radical first and mix it again with methanol so that the absorbance value at 732 nm is 0.8 ± 0.2. The adjusted ABTS reagent was used.
구체적으로는 ABTS 시약 0.9 mL에 각각의 분석시료 0.1 mL를 첨가하여 3분간 반응시킨 후 즉시 732 nm에서 흡광도를 측정하였다. 음성 대조구는 시료 대신 증류수를 사용하여 동일한 방법으로 수행하여 흡광도의 차이를 상기 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 3b에 나타내었다.Specifically, 0.1 mL of each analysis sample was added to 0.9 mL of ABTS reagent, reacted for 3 minutes, and absorbance was measured immediately at 732 nm. The negative control was performed in the same way using distilled water instead of the sample to calculate the difference in absorbance as a percentage (%) by the above formula, and the results are shown in FIG. 3B.
도 3b에 도시된 바와 같이, 200배 희석한 경우 비교예는 66.65%, 실시예는 90.78%의 소거활성을 나타내어, 실시예가 약 40% 증진된 것을 알 수 있다.As shown in FIG. 3B, when diluted 200-fold, the comparative example exhibited a scavenging activity of 66.65% and the example 90.78%, suggesting that the example was improved by about 40%.
<FRAP 환원력><FRAP reducing power>
FRAP (ferric reducing antioxidant power) 환원력은 화합물들의 환원력을 측정하는 방법으로 Fe3 + 이온을 Fe2 + 이온으로 환원시키는 능력을 흡광도 수치를 이용하여 측정하는 방법이다.FRAP (ferric reducing antioxidant power) is a method of measuring the reducing power of compounds and is a method of measuring the ability to reduce Fe 3 + ions to Fe 2 + ions using absorbance values.
상세하게는 아세테이트 버퍼(30 mM, pH 3.6), TPTZ 시약 (10 mM in 40 mM HCl), 및 FeCl3 용액(20 mM 함유 증류수)을 10:1:1 (v/v/v)의 비율로 혼합하여 FRAP 측정 시약을 조제하여 37℃ 항온기에서 15분간 예비반응시켜 두었다. 각각의 분석시료 50 ㎕와 FRAP 시약 950 ㎕를 분주하여 37℃에서 15분 반응시키고 595 nm에서 흡광도를 측정하였고 그 결과를 도 3c에 나타냈다.Specifically, acetate buffer (30 mM, pH 3.6), TPTZ reagent (10 mM in 40 mM HCl), and FeCl 3 The solution (20 mM-containing distilled water) was mixed at a ratio of 10: 1: 1 (v / v / v) to prepare a FRAP measuring reagent and pre-reacted for 15 minutes in a 37 ° C incubator. 50 μl of each analysis sample and 950 μl of FRAP reagent were dispensed, reacted at 37 ° C. for 15 minutes, and absorbance was measured at 595 nm, and the results are shown in FIG. 3C.
도 3c에 도시된 바와 같이, 200배 희석한 경우 비교예는 0.678의 환원력을 나타냈지만 실시예는 환원력이 1.039으로 실시예가 약 50% 증진된 것을 알 수 있다.As shown in Figure 3c, when diluted 200-fold, the comparative example showed a reducing power of 0.678, but it can be seen that the working example has a reducing power of 1.039, which is about 50% improvement.
시험예Test example 4. 4. 항당뇨Anti-diabetes 및 And 항비만Antiobesity 효과 분석 Effect analysis
항당뇨 효과 측정은 지표인 알파-글루코시다아제와 항비만 효과의 지표인 췌장-리파아제를 사용하여 두 가지 효소 저해활성을 통해 분석하여 실시하였다.The anti-diabetic effect was measured and analyzed through two enzyme inhibitory activities using alpha-glucosidase, an index, and pancreatic-lipase, an index of anti-obesity effects.
<알파-글루코시다아제 저해활성><Alpha-glucosidase inhibitory activity>
실시예의 도라지 액상조성물과 비교예의 도라지 액상조성물을 증류수로 100배, 50배, 20배 희석한 분석시료를 각각 50 ㎕, 알파-글루코시다아제(1.0 U/mL) 50 ㎕, 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37℃에서 10분간 예비반응시켰다. 그리고 나서 인산나트륨 완충용액(pH 6.8)에 녹인 p-NPG(5 mM) 100 ㎕를 첨가하여 다시 37℃에서 10분 반응시켰다. 이 반응액에 Na2CO3 (100 mM) 0.75 mL를 가해 최종 반응을 정지시킨 후 420 nm에서 흡광도를 측정하고 음성대조구로 증류수를 사용하여 상기 식에 의해 백분율(%)을 계산하였고 도 4a에 나타내었다. 50 μl of the assay samples diluted 100 times, 50 times, and 20 times of the bellflower liquid composition of the example and the bellflower liquid composition of the comparative example with distilled water, 50 μl of alpha-glucosidase (1.0 U / mL), and buffered 200
도 4a에 도시된 바와 같이, 본 발명에 따른 도라지 액상조성물들은 비교예에 비하여 증진된 효소저해활성을 나타내었고, 20배 희석한 경우 비교예(30.66%)보다 실시예(43.82%)는 현저히 증진되었다. As shown in Figure 4a, the bellflower liquid composition according to the present invention exhibited an enhanced enzyme inhibitory activity compared to the comparative example, the Example (43.82%) significantly improved than the comparative example (30.66%) when diluted 20-fold Became.
<췌장-리파아제 저해활성><Pancreatic-lipase inhibitory activity>
실시예의 도라지 액상조성물과 비교예의 도라지 액상조성물을 증류수로 100배, 50배, 20배 희석한 분석시료를 각가 50 ㎕, 리파아제(1.0 U/mL) 50 ㎕, 및 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37 ℃에서 10분간 예비반응시켰다. 반응 후 인산나트륨 완충용액에 녹인 p-NPB (5 mM) 100㎕를 첨가하여 동일하게 10분간 반응시킨 후 100 mM Na2CO3 0.75 mL를 첨가해 반응을 정지시켜 420 nm에서 흡광도를 측정하였다. 음성대조구는 시료 대신에 증류수를 취하였으며 시료용액의 첨가구와 무첨가구 사이의 흡광도 차이를 상기 식에 의해 백분율(%)로 산출하였고, 그 결과를 도 4b에 나타냈다. 100 μl, 50 times, and 20 times diluted samples of the bellflower liquid composition of the example and the bellflower liquid composition of the comparative example with 50 μl each, 50 μl of lipase (1.0 U / mL), and 200 μm sodium phosphate buffer solution (pH 6.8) 50 µl was mixed and pre-reacted at 37 ° C for 10 minutes. After the reaction, 100 μl of p-NPB (5 mM) dissolved in a sodium phosphate buffer solution was added and reacted for 10 minutes, followed by 100 mM Na 2 CO 3 The reaction was stopped by adding 0.75 mL to measure absorbance at 420 nm. For the negative control, distilled water was taken instead of the sample, and the difference in absorbance between the addition and non-addition of the sample solution was calculated as a percentage (%) by the above formula, and the results are shown in FIG. 4B.
도 4b에 도시된 바와 같이, 본 발명에 따른 도라지 액상조성물들은 비교예에 비하여 현저히 증진된(약 0.4 ~ 3배) 효소저해활성을 나타내었다.As shown in Figure 4b, the bellflower liquid composition according to the present invention showed a significantly enhanced (about 0.4 ~ 3 times) enzyme inhibitory activity compared to the comparative example.
시험예Test example 5. 이화학적 특성 분석 5. Analysis of physicochemical properties
실시예와 비교예의 액상 조성물의 pH, 산도, 가용성 고형물, 환원당 및 수용성 단백질 함량을 측정하였다. The liquid compositions of Examples and Comparative Examples were measured for pH, acidity, soluble solids, reducing sugar and water-soluble protein content.
pH는 pH 미터기(MP 200, UK)로 측정하였고, 산도는 0.1 N NaOH를 사용하여 pH 8.2±0.2까지 중화시켰을 시 소요되는 소비량을 젖산양으로 환산하여 %로 표시하였고, 가용성 고형물 함량은 굴절 당도계를 사용하여 측정하였다. 환원당은 DNS법에 따라 각각의 분석시료 0.1 mL에 DNS 시약 1 mL를 첨가하여 100℃에서 20분 발색시킨 후 급속히 냉각하고 분광광도계를 사용하여 570 nm에서 흡광도를 측정하여 검량선과 비교하였다.The pH was measured with a pH meter (
수용성 단백질 함량은 biuret법을 통하여 실시하였다. 즉, CuSO4·5H2O (황산구리 5수화물) 1.5 g에 KNaC4H4O6·4H2O (주석산칼륨 나트륨) 6.0 g을 500 mL의 증류수에 녹이고 10% NaOH 300 mL를 가한 후 최종 부피가 1,000 mL가 되게끔 정용하여 biuret 시약을 제조하였다. 각각의 분석시료 1 g을 시험관에 취하고 여기에 biuret 시약 4 mL를 첨가 및 혼합하여 37℃에서 20분간 반응시켰다. 이때 음성대조구는 증류수를 취하여 진행하였으며 20분 반응 후 3분간 원심분리 하여 상등액을 540 nm에서 흡광도를 측정하고 단백질 표준곡선(bovine serum albumin)에 의해 산출된 계산식에 따라 수용성 단백질을 정량하여 표 4에 나타내었다.The water-soluble protein content was carried out through the biuret method. That is, CuSO 4 · 5H 2 O (copper sulfate pentahydrate) 1.5 g of KNaC 4 H 4 O 6 · 4H 2 O (sodium potassium stannate) 6.0 g was dissolved in 500 mL of distilled water and 300 mL of 10% NaOH was added to the final volume. Was prepared to be 1,000 mL to prepare a biuret reagent. 1 g of each analytical sample was taken in a test tube, and 4 mL of biuret reagent was added thereto and mixed to react at 37 ° C for 20 minutes. At this time, the negative control was conducted by taking distilled water, and after 20 minutes of reaction, centrifugation was performed to measure the absorbance of the supernatant at 540 nm and quantify the water-soluble protein according to the calculation formula calculated by the protein standard curve (bovine serum albumin). Shown.
(%, 젖산)Acidity
(%, Lactic acid)
(Brix, %)Soluble solids
(Brix,%)
(mg/mL)Reducing sugar
(mg / mL)
표 5에 나타낸 바와 같이, 비교예가 가용성 고형분, 환원당 함량, 및 수용성 단백질 함량은 비교예가 실시예 보다 높았다.As shown in Table 5, the comparative example had higher soluble solid content, reduced sugar content, and water-soluble protein content than the comparative example.
Claims (5)
상기 숙성 도라지 농축액은 도라지를 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복한 후 여과하여 농축하여 제조되고,
상기 복합발효된 활성산양삼 추출액은 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복한 후 수탁번호 KACC 92157P로 기탁된 락토바실러스 브레비스 BMK484 균주와 수탁번호 KACC91848P로 기탁된 락토바실러스 플란타륨 P1201 균주의 복합 종균으로 발효하고 여과하여 제조되는 것인
인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이가 강화된 스틱형 용기용 도라지 액상조성물.
Aged bellflower concentrate 26 ~ 30% by volume, complex fermented active ginseng extract 3 ~ 5% by volume, black garlic concentrate 5 ~ 7% by volume, liquid sugars 45 ~ 55% by volume, and remaining water,
The aged bellflower concentrate is prepared by repeating hot boiled ginseng at 100 ° C for 30-60 minutes and hot aged ginseng for 2-4 days at 70-90 ° C three times, followed by filtration and concentration.
The complex fermented active goat ginseng extract is a lactobacillus brevis deposited with goat ginseng at 100 ℃ for 30 ~ 60 minutes and hot boiled ginseng at a temperature of 70 ~ 90 ℃ for 2-4 days after repeated three times. It is prepared by fermenting and filtering with a complex strain of BMK484 strain and Lactobacillus plantarium P1201 strain deposited with accession number KACC91848P
Human-absorbed ginsenoside Rd2, F2, Rg3, and a bellflower liquid composition for stick-type containers reinforced with compound K.
The liquid composition of claim 1, wherein the content of ginsenosides Rd2, F2, Rg3 and compound K is 0.14 mg / mL or more, 0.05 mg / mL or more, 0.11 mg / mL or more, and 0.05 mg / mL or more, respectively. Characterized in that the body absorption type ginsenoside Rd2, F2, Rg3 and the compound k bellflower liquid composition for stick-type containers reinforced.
According to claim 1, Human body absorption type ginsenosides Rd2, F2, Rg3 and compound K is enhanced bellflower liquid composition for stick containers, characterized by having enhanced antioxidant activity, anti-diabetic activity and anti-obesity activity.
Functional food for improving antioxidant and diabetes and obesity comprising the liquid composition according to claim 1.
ⅱ) 산양삼을 100℃에서 30~60분간 증숙과 증숙된 산양삼을 70∼90℃에서 2~4일 고온숙성을 3회 반복한 후 수탁번호 KACC 92157P로 기탁된 락토바실러스 브레비스 BMK484 균주와 수탁번호 KACC91848P로 기탁된 락토바실러스 플란타륨 P1201 균주의 복합 종균으로 발효하여 추출하여 복합발효된 삼양삼 추출액을 제조하는 단계; 및
ⅲ) 숙성 도라지 농축액 26~30 부피%, 복합발효된 활성산양삼 추출액 3~5 부피%, 흑마늘 농축액 5∼7 부피%, 액상당류 45~55 부피% 및 나머지 물을 혼합하여 스틱형 용기에 충진하는 단계를 포함하여 이루어지는 인체 흡수형 진세노사이드 Rd2, F2, Rg3 및 컴파운드 케이가 강화된 스틱형 용기용 도라지 액상조성물의 제조방법.Iv) preparing the matured bellflower concentrate by repeating the evaporation of the bellflower at 100 ° C for 30 to 60 minutes and the high temperature aging for 2 to 4 days at 70 to 90 ° C for 3-4 days;
Ii) After boiling the wild ginseng at 100 ℃ for 30 ~ 60 minutes and hot aged ginseng at 70 ~ 90 ℃ for 2-4 days after repeating it three times, Lactobacillus Brevis BMK484 strain deposited with accession number KACC 92157P and accession number KACC91848P Deposited with Preparing a fermented Samyang ginseng extract by fermenting and extracting a complex seed of the Lactobacillus plantarium P1201 strain; And
Iv) 26 ~ 30% by volume of aged bellflower concentrate, 3 ~ 5% by volume of complex fermented active ginseng extract, 5 ~ 7% by volume of black garlic concentrate, 45 ~ 55% by volume of liquid sugar, and the remaining water to fill the stick-type container A method of manufacturing a bellflower liquid composition for a stick-type container in which a human-absorbing ginsenoside Rd2, F2, Rg3, and a compound K are strengthened, comprising steps.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180132540A KR102132537B1 (en) | 2018-10-31 | 2018-10-31 | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180132540A KR102132537B1 (en) | 2018-10-31 | 2018-10-31 | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200049356A true KR20200049356A (en) | 2020-05-08 |
| KR102132537B1 KR102132537B1 (en) | 2020-07-09 |
Family
ID=70677148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180132540A KR102132537B1 (en) | 2018-10-31 | 2018-10-31 | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102132537B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220143999A (en) | 2021-04-16 | 2022-10-26 | 금산덕원인삼약초영농조합법인 | manufacturing methods of balloon flower hydrolysis concentration |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090039933A (en) * | 2007-10-19 | 2009-04-23 | (주) 행복에프씨 | Preparation method for aged bellflower |
| KR20110093477A (en) * | 2010-02-12 | 2011-08-18 | 서원대학교산학협력단 | Antitumor composition comprising fermented red ginseng |
| KR20180006738A (en) * | 2016-07-11 | 2018-01-19 | 주식회사 위드네이처 | Method for producing fermented korean cultivated wild ginseng with enhanced specific ginsenoside content using lactic acid bacteria |
| KR20180102358A (en) * | 2017-03-07 | 2018-09-17 | 함양군 | Wild Cultivated Ginseng Mixed concentrate and Production method thereof, Production shipment method of Wild Cultivated Ginseng Mixed concentrate liquid stick set |
-
2018
- 2018-10-31 KR KR1020180132540A patent/KR102132537B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090039933A (en) * | 2007-10-19 | 2009-04-23 | (주) 행복에프씨 | Preparation method for aged bellflower |
| KR20110093477A (en) * | 2010-02-12 | 2011-08-18 | 서원대학교산학협력단 | Antitumor composition comprising fermented red ginseng |
| KR20180006738A (en) * | 2016-07-11 | 2018-01-19 | 주식회사 위드네이처 | Method for producing fermented korean cultivated wild ginseng with enhanced specific ginsenoside content using lactic acid bacteria |
| KR20180102358A (en) * | 2017-03-07 | 2018-09-17 | 함양군 | Wild Cultivated Ginseng Mixed concentrate and Production method thereof, Production shipment method of Wild Cultivated Ginseng Mixed concentrate liquid stick set |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220143999A (en) | 2021-04-16 | 2022-10-26 | 금산덕원인삼약초영농조합법인 | manufacturing methods of balloon flower hydrolysis concentration |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102132537B1 (en) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101301094B1 (en) | Composition for relieving hangover or improving liver function | |
| KR20200054864A (en) | Complex-fermented composition of Fabaton soybean leaves and Schisandra chinensis having enhanced anti-diabetic and anti-obesity effects and preparation method thereof | |
| KR101253658B1 (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
| KR101963046B1 (en) | Composition of processed ginseng having increased ginsenoside compound K, chlorgenic acid and quercetin, and preparation method thereof | |
| KR20220025680A (en) | Method for producing fermented balloon flower postbiotics with increased effective component content using lactic acid bacteria | |
| KR102132537B1 (en) | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof | |
| KR102150162B1 (en) | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof | |
| KR20160126591A (en) | Method of producing ginseng fermented extract, Ginseng fermented extract produced by the same and Health functional foods comprising the same | |
| KR102094084B1 (en) | Aged and complex-fermented mountain-cultivated ginseng having increased ginsenosides of human body absorption type and omega-6 fatty acid, and preparation method thereof | |
| KR102090408B1 (en) | Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof | |
| KR100848686B1 (en) | A FERMENTED GINSENG COMPOSITION STRENGTHENED SIMULTANEOUSLY WITH γ-AMINOBUTYRIC ACID AND BIOCONVERSION SAPONIN BY LACTIC ACID BACTERIA | |
| KR20200078171A (en) | The manufacturing method of fermented red ginseng extracts enhanced with ginsenoside compound K, Rd and Rd3 using β-glucosidase and lactic acid bacteria | |
| CN113767986A (en) | Modified milk powder beneficial to cardiovascular health and preparation method thereof | |
| KR102294897B1 (en) | manufacturing method of fermented food | |
| KR101482044B1 (en) | Food composition comprising fermented product of Pleuropterus multiflorus and ginger for alleviating or preventing degenerative brain disorder and method of producing the same | |
| KR20220087888A (en) | Black bellflower syrup and method of preparing therefor | |
| KR101970320B1 (en) | Composition for preventing, improving or treating respiratory diseases comprising fermented solution of Chaenomeles sinensis as effective component and production method thereof | |
| JP2005224205A (en) | Health food | |
| KR101668447B1 (en) | Composition for curing hanover and health functional foods composition comprising the same | |
| KR20210050103A (en) | Immune enhancing liquid composition having increased ginsenosides Rb1, Rg1 and Rg3 and preparation method thereof | |
| KR20200132439A (en) | Method for Manufacturing Fermented Ginseng Tablet | |
| KR102365198B1 (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume, Polygonum multiflorum Thunberg and mountain ginseng | |
| KR102259131B1 (en) | The manufacturing method of fermented red ginseng extracts enhanced with ginsenoside compound K, Rd and Rd3 using β-glucosidase and lactic acid bacteria | |
| KR20210072290A (en) | Liquid ginseng composition containing high ginsenoside F2, Rg3 and compound K, chlorogenic acid and quercetin and preparation method thereof | |
| KR101328179B1 (en) | Preparation method of fermented red ginseng having high ginsenoside contents using surface culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right |